CORPORATE INFORMATION

陳啟宇
吳以芳
關曉暉

晏子厚
傅潔民

蘇德揚
陳力元
趙國屏
宋瑞霖

馮蓉麗
孔德力
王靜怡
周勇
戴昆

蘇德揚
陳力元
關曉暉

陳啟宇
趙國屏
宋瑞霖

宋瑞霖
陳力元
吳以芳

陳啟宇

吳以芳

晏子厚
蘇德揚
宋瑞霖
傅潔民

陳力元
蘇德揚
宋瑞霖
晏子厚

郭新軍
梁晶晶

晏子厚

傅潔民

馮蓉麗

周勇

戴昆

梁晶晶

OPERATION HIGHLIGHTS


漢利康

漢曲優

上海市藥品監督管理局

漢曲優

OPERATION HIGHLIGHTS



《藥品生產現場檢查結果告知書》

漢曲優

1. MAB BIOSIMILARS THAT ARE EXPECTED TO BE COMMERCIALISED IN THE NEAR FUTURE

2. CONTINUOUS AND EFFICIENT ADVANCEMENT ON CLINICAL RESEARCH PRODUCTS

3. ACCELERATING THE DEVELOPMENT OF MULTIPLE PRE-CLINICAL RESEARCH PROJECTS

漢利康

漢曲
優

漢曲優

漢曲優

漢利康

(II) FORWARD-LOOKING PRODUCTION CAPACITY LAYOUT WITH HIGH COST-EFFICIENCY

《藥品生產現場檢查結果告知書》

漢曲優

《藥品生產現場檢查結果告知書》

(III) ADVANCED COMMERCIALISATION STRATEGY AND LAYOUT

- **COMMERCIALISATION PLANNING FOR HLX01漢利康 (PRODUCTS TREATING HAEMATOLOGICAL TUMOURS)**

漢利康

漢利康

漢利康

漢利康

漢利康

漢利康

漢利康

漢利康

漢利康

漢

利康

- **COMMERCIALISATION PLANNING FOR HLX02 漢曲優 (PRODUCTS TREATING BREAST CANCER AND GASTRIC CANCER)**

漢曲優

漢曲優

- COMMERCIALISATION PLANNING FOR HLX03 PRODUCTS (PRODUCTS TREATING AUTOIMMUNE DISEASES)

優立通

江蘇萬邦雲健康科技有限公司

(IV) RESULTS OF INTERNATIONALISED LAYOUT

(I) CAPITALISE ON FIRST-ENTRANT ADVANTAGES AND ACCELERATE THE LAUNCH OF COMMERCIAL SALES

(II) MAINTAIN HIGH-QUALITY STANDARDS AND EFFICIENTLY PLAN PRODUCTION CAPACITY CONSTRUCTION AND UTILISATION

(III) ACTIVELY PROMOTE R&D OF INNOVATIVE DRUGS BASED ON OUR EXTENSIVE PIPELINE

公共安全風險防控與應急技術

裝備

(IV) MAINTAIN EFFICIENT OPERATIONS AND FURTHER PROMOTE THE IMPLEMENTATION OF INTERNATIONALISATION STRATEGIES

(I) REVENUE

漢利康

漢利康

漢利康

漢利康

漢利康

漢利康

(II) COST OF SALES

漢利康

(III) GROSS PROFIT

（漢利康）

(IV) OTHER INCOME AND GAINS

		–

(V) R&D EXPENDITURE

(VI) ADMINISTRATIVE EXPENSES

(VII) SELLING AND DISTRIBUTION EXPENSES

OTHER EXPENSES

INCOME TAX EXPENSE

(X) LOSS FOR THE PERIOD

(XI) LIQUIDITY AND CAPITAL RESOURCES

) TRADE RECEIVABLES

漢利康

INTEREST-BEARING BANK AND OTHER BORROWINGS

漢利康

MATURITY STRUCTURE OF OUTSTANDING DEBTS

)COLLATERAL AND PLEDGED ASSETS

KEY FINANCIAL .

CONTINGENT LIABILITIES

) MATERIAL ACQUISITIONS AND DISPOSALS

INTERIM DIVIDENDS

(I) FOREIGN EXCHANGE RISK

(II) EXCHANGE RATE RISK

(III) POTENTIAL RISKS

1. MARKET RISK

2. BUSINESS AND OPERATIONAL RISK

3. POTENTIAL RISKS OF COVID-19

INDEPENDENT REVIEW REPORT



Ernst & Young
22/F, CITIC Tower
1 Tim M·—

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	–	–

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	–	–	–	–		
	–	–	–		–	
	–	–	–			
	–			–	–	
	–	–		–	–	
	–	–	–	–		
	–	–	–		–	

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

			–
			–
		–	
		–	–

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


2.1. BASIS OF PREPARATION

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

		—







) TRANSACTIONS WITH RELATED PARTIES

		–	
			–
			–
			–
			–
		–	
			–
			–


) TRANSACTIONS WITH RELATED PARTIES

) OUTSTANDING BALANCES WITH RELATED PARTIES

		–
		–
		–
		–
		–
		–
	–	

) COMPENSATION OF KEY MANAGEMENT PERSONNEL OF THE GROUP





GENERAL INFORMATION

(B) INTERESTS IN SHARES OF ASSOCIATED CORPORATIONS

2. PROPOSED A SHARE OFFERING ON THE SHANGHAI STOCK EXCHANGE

	《生物類似藥研發與評價技術指導原則（試行）》
	復星控股有限公司
	復星國際控股有限公司
	上海復星高科技（集團）有限公司

復星國際有限公司

上海復星新藥研究有限公司

上海復星醫藥（集團）股份有限公司

上海復星醫藥產業發展有限公司